Previous reports had highlighted differential activity and response of RT-DLBCL cells to novel targeted agents such as BCL2 inhibitor venetoclax, and BTK inhibitor ibrutinib [11, 12, 14]. Here, BCL2 is linked to diffuse large B-cell lymphoma.